FBRX NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Forte Biosciences Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 76.60 USD
39.8% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 155.9% above the Trend Line and sits at 99.1% of its 52-week range. The latest completed week returned 39.8%, after a 266.2% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 52/100 conviction, while the latest news-sentiment score is 58/100. Near-term considerations: price is close to its 52-week high; earnings are due in 11d.

Setup score 65 out of 100
Latest Close 76.60 USD 31 Jul 2026
1W Return 39.8% latest completed week
4W Return 266.2% short-term follow-through
12W Return 218.9% quarterly tape
Trend Breadth 80.8% 42 of 52 weeks active
Volume Ratio 6.6x vs 13-week average
What is working
  • The trend backdrop is active with a 2-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • Activity pressure is weak, so confirmation is not yet broad enough.
  • 8 reversal markers appear in the recent smart-money tape.
  • Recent volatility is running well above the one-year baseline.
What to watch next
  • Price is close to its 52-week high; watch for continuation or exhaustion.
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 39.8% Latest completed week; four-week move 266.2%. Indicator stack 51/92 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Volatility 52/100 conviction; expected move 40.3%. News sentiment 58/100 60 relevant articles in the latest sentiment read. Event risk 11d Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 155.9% above the Trend Line and sits at 99.1% of its 52-week range. The latest completed week returned 39.8%, after a 266.2% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 6.6x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.4212-week average 0.43

12-week confirmation

Trend active3/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure3/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership5/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.42Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers88 reversal markers

No recent accumulation markers. 8 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 266.2% over four weeks, 218.9% over 12 weeks, and 697.1% over one year. The current trend has remained active for 2 consecutive weeks.

Performance by holding period

1W39.8%
4W266.2%
12W218.9%
26W161.7%
52W697.1%
Active trend streak2 weeks
Active weeks in one year42
Trend breadth80.8%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.35Latest activity-pressure read.
Pressure change226.4%Four-week change in activity pressure.
Leadership196.35Latest relative-leadership reading.
RS change1960.1%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 64% Model confidence 61%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength80/100Blend of value, momentum, and quality. Underlying universe rank 21; rank 1 is best.
Value65/100Relative valuation strength. Underlying universe rank 36; rank 1 is best.
Quality63/100Profitability and accounting quality. Underlying universe rank 38; rank 1 is best.
Momentum65/100Medium-term price momentum. Underlying universe rank 36; rank 1 is best.
Growth65/100Revenue and earnings growth. Underlying universe rank 36; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-5.6%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
1/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-6.7%
Net share repurchases relative to market value.
Shareholder yield
-6.7%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.8x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

FBRX shows volatility options pressure with a 52/100 conviction score, put-call volume ratio of 0.42, expected move of 40.3%, and Sharemaestro trend signal active.

Conviction52/100
Expected move40.3%
Put/call volume0.42
Pressure29
Speculation44
Volatility89
Trend agreement83
Open options detail
Insider activity10 / 4

10 acquisitions and 4 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment58/100

Weighted news tone is neutral across 60 relevant articles.

25 positive · 30 neutral · 5 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings11dNext report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
Options expected move40.3%Nearest-chain priced movement where available.
52-week drawdown-0.8%Distance below the 52-week high.
13-week volatility31.9%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher13 of 2613 weeks finished lower.
Best week+109.9%Week of 10 Jul.
Worst week-19.1%Week of 24 Apr.
Latest week+39.8%Week of 31 Jul.

Shape of recent returns

Strong gains10
Modest gains3
Flat weeks0
Modest losses3
Sharp losses10
Recent vol31.9%13-week weekly-return volatility.
Base vol20.7%52-week weekly-return volatility.
Up/down split29/23Count of positive and negative weeks in the 52-week window.
Average skew16.6% / -8.1%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape60/100

Trend, activity pressure, participation, and risk combine to a 60/100 tape read.

 Indicator analysis27/100

Latest 12-week confirmation: trend 3/12, activity pressure 3/12, relative leadership 5/12.

Activity pressure 0.42; 8 reversal markers Factors68/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 84; Small Cap Core rank 44 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options59/100

FBRX shows volatility options pressure with a 52/100 conviction score, put-call volume ratio of 0.42, expected move of 40.3%, and Sharemaestro trend signal active.

Volatility · Volatility expansion watch · Expected move 40.3% Sentiment58/100

Weighted news tone is neutral across 60 relevant articles.

Price to earnings forward of Forte Biosciences, Inc. – NASDAQ:FBRX Insiders10 / 4

10 acquisitions and 4 disposals in the latest 180-day insider tape.

 Earnings11d

Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202676.60 USD39.8%29.93 USD17.03 USD1.35196.3530.5MOn
24 Jul 202654.78 USD12.1%28.17 USD16.68 USD0.73123.863.4MOn
17 Jul 202648.86 USD11.2%27.27 USD16.49 USD0.29102.973.4MOff
10 Jul 202643.92 USD109.9%26.63 USD16.33 USD-0.4080.079.3MOff
3 Jul 202620.92 USD-0.5%25.88 USD16.21 USD-1.07-10.561.6MOff
26 Jun 202621.03 USD17.8%25.84 USD16.24 USD-1.25-9.064.1MOff
19 Jun 202617.85 USD1.7%25.76 USD16.27 USD-1.59-25.97696.1KOff
12 Jun 202617.56 USD6.3%25.78 USD16.32 USD-1.58-25.391.3MOff
5 Jun 202616.52 USD-13.4%25.67 USD16.37 USD-1.48-28.131.8MOff
29 May 202619.07 USD-11.7%25.52 USD16.42 USD-1.37-20.68869.3KOff
22 May 202621.59 USD-6.6%25.31 USD16.47 USD-1.12-7.091.2MOff
15 May 202623.11 USD-3.8%25.00 USD16.49 USD-0.971.471.1MOn
8 May 202624.02 USD-14.8%24.63 USD16.50 USD-0.646.23934.7KOn
1 May 202628.19 USD2.7%24.34 USD16.52 USD-0.2033.201.2MOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.